184 related articles for article (PubMed ID: 35804930)
21. NVP-BEZ235, dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, prominently enhances radiosensitivity of prostate cancer cell line PC-3.
Zhu W; Fu W; Hu L
Cancer Biother Radiopharm; 2013 Nov; 28(9):665-73. PubMed ID: 23768063
[TBL] [Abstract][Full Text] [Related]
22. Dual inhibitor of phosphoinositide 3-kinase/mammalian target of rapamycin NVP-BEZ235 effectively inhibits cisplatin-resistant urothelial cancer cell growth through autophagic flux.
Li JR; Cheng CL; Yang CR; Ou YC; Wu MJ; Ko JL
Toxicol Lett; 2013 Jul; 220(3):267-76. PubMed ID: 23651616
[TBL] [Abstract][Full Text] [Related]
23. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with nilotinib against BCR-ABL-positive leukemia cells involves the ABL kinase domain mutation.
Okabe S; Tauchi T; Tanaka Y; Kitahara T; Kimura S; Maekawa T; Ohyashiki K
Cancer Biol Ther; 2014 Feb; 15(2):207-15. PubMed ID: 24100660
[TBL] [Abstract][Full Text] [Related]
24. Genotype-dependent efficacy of a dual PI3K/mTOR inhibitor, NVP-BEZ235, and an mTOR inhibitor, RAD001, in endometrial carcinomas.
Shoji K; Oda K; Kashiyama T; Ikeda Y; Nakagawa S; Sone K; Miyamoto Y; Hiraike H; Tanikawa M; Miyasaka A; Koso T; Matsumoto Y; Wada-Hiraike O; Kawana K; Kuramoto H; McCormick F; Aburatani H; Yano T; Kozuma S; Taketani Y
PLoS One; 2012; 7(5):e37431. PubMed ID: 22662154
[TBL] [Abstract][Full Text] [Related]
25. Synergistic antitumor effect of NVP-BEZ235 and sunitinib on docetaxel-resistant human castration-resistant prostate cancer cells.
Park HS; Hong SK; Oh MM; Yoon CY; Jeong SJ; Byun SS; Cheon J; Lee SE; Moon du G
Anticancer Res; 2014 Jul; 34(7):3457-68. PubMed ID: 24982354
[TBL] [Abstract][Full Text] [Related]
26. Roscovitine strongly enhances the effect of olaparib on radiosensitivity for HPV neg. but not for HPV pos. HNSCC cell lines.
Ziemann F; Seltzsam S; Dreffke K; Preising S; Arenz A; Subtil FSB; Rieckmann T; Engenhart-Cabillic R; Dikomey E; Wittig A
Oncotarget; 2017 Dec; 8(62):105170-105183. PubMed ID: 29285242
[TBL] [Abstract][Full Text] [Related]
27. Efficacy of the dual PI3K and mTOR inhibitor NVP-BEZ235 in combination with imatinib mesylate against chronic myelogenous leukemia cell lines.
Xin P; Li C; Zheng Y; Peng Q; Xiao H; Huang Y; Zhu X
Drug Des Devel Ther; 2017; 11():1115-1126. PubMed ID: 28435223
[TBL] [Abstract][Full Text] [Related]
28. NVP-BEZ235, a novel dual PI3K-mTOR inhibitor displays anti-glioma activity and reduces chemoresistance to temozolomide in human glioma cells.
Yu Z; Xie G; Zhou G; Cheng Y; Zhang G; Yao G; Chen Y; Li Y; Zhao G
Cancer Lett; 2015 Oct; 367(1):58-68. PubMed ID: 26188279
[TBL] [Abstract][Full Text] [Related]
29. Dual blocking of PI3K and mTOR signaling by NVP-BEZ235 inhibits proliferation in cervical carcinoma cells and enhances therapeutic response.
Xie G; Wang Z; Chen Y; Zhang S; Feng L; Meng F; Yu Z
Cancer Lett; 2017 Mar; 388():12-20. PubMed ID: 27894954
[TBL] [Abstract][Full Text] [Related]
30. Targeting DNA damage response in head and neck cancers through abrogation of cell cycle checkpoints.
Molkentine JM; Molkentine DP; Bridges KA; Xie T; Yang L; Sheth A; Heffernan TP; Clump DA; Faust AZ; Ferris RL; Myers JN; Frederick MJ; Mason KA; Meyn RE; Pickering CR; Skinner HD
Int J Radiat Biol; 2021; 97(8):1121-1128. PubMed ID: 32073931
[TBL] [Abstract][Full Text] [Related]
31. Levels of p27 sensitize to dual PI3K/mTOR inhibition.
Lee M; Theodoropoulou M; Graw J; Roncaroli F; Zatelli MC; Pellegata NS
Mol Cancer Ther; 2011 Aug; 10(8):1450-9. PubMed ID: 21646547
[TBL] [Abstract][Full Text] [Related]
32. Wee-1 Kinase Inhibition Sensitizes High-Risk HPV+ HNSCC to Apoptosis Accompanied by Downregulation of MCl-1 and XIAP Antiapoptotic Proteins.
Tanaka N; Patel AA; Wang J; Frederick MJ; Kalu NN; Zhao M; Fitzgerald AL; Xie TX; Silver NL; Caulin C; Zhou G; Skinner HD; Johnson FM; Myers JN; Osman AA
Clin Cancer Res; 2015 Nov; 21(21):4831-44. PubMed ID: 26124202
[TBL] [Abstract][Full Text] [Related]
33. Dual PI3K/mTOR inhibitor NVP-BEZ235-induced apoptosis of hepatocellular carcinoma cell lines is enhanced by inhibitors of autophagy.
Chang Z; Shi G; Jin J; Guo H; Guo X; Luo F; Song Y; Jia X
Int J Mol Med; 2013 Jun; 31(6):1449-56. PubMed ID: 23588698
[TBL] [Abstract][Full Text] [Related]
34. Dual inhibitor of PI3K and mTOR (NVP-BEZ235) augments the efficacy of fluorouracil on gastric cancer chemotherapy.
Li L; Zhang S; Xie D; Chen H; Zheng X; Pan D
Onco Targets Ther; 2018; 11():6111-6118. PubMed ID: 30275715
[TBL] [Abstract][Full Text] [Related]
35. Autophagy inhibition enhances colorectal cancer apoptosis induced by dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235.
Yang X; Niu B; Wang L; Chen M; Kang X; Wang L; Ji Y; Zhong J
Oncol Lett; 2016 Jul; 12(1):102-106. PubMed ID: 27347108
[TBL] [Abstract][Full Text] [Related]
36. Downregulation of SMG-1 in HPV-positive head and neck squamous cell carcinoma due to promoter hypermethylation correlates with improved survival.
Gubanova E; Brown B; Ivanov SV; Helleday T; Mills GB; Yarbrough WG; Issaeva N
Clin Cancer Res; 2012 Mar; 18(5):1257-67. PubMed ID: 22247495
[TBL] [Abstract][Full Text] [Related]
37. Identification of four key prognostic genes and three potential drugs in human papillomavirus negative head and neck squamous cell carcinoma.
Tian G; Fu Y; Zhang D; Li J; Zhang Z; Yang X
Cancer Cell Int; 2021 Mar; 21(1):167. PubMed ID: 33712015
[TBL] [Abstract][Full Text] [Related]
38. Effects of NVP-BEZ235, a dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor, on HTLV-1-infected T-cell lines.
Ishikawa C; Senba M; Mori N
Oncol Lett; 2018 Apr; 15(4):5311-5317. PubMed ID: 29552172
[TBL] [Abstract][Full Text] [Related]
39. The dual PI3K/mTOR inhibitor BEZ235 restricts the growth of lung cancer tumors regardless of EGFR status, as a potent accompanist in combined therapeutic regimens.
Wu YY; Wu HC; Wu JE; Huang KY; Yang SC; Chen SX; Tsao CJ; Hsu KF; Chen YL; Hong TM
J Exp Clin Cancer Res; 2019 Jul; 38(1):282. PubMed ID: 31262325
[TBL] [Abstract][Full Text] [Related]
40. Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against osteosarcoma.
Zhu YR; Min H; Fang JF; Zhou F; Deng XW; Zhang YQ
Cancer Biol Ther; 2015; 16(4):602-9. PubMed ID: 25869769
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
